MedQuist sees 34% increase in Q3 revenue
MedQuist is a provider of integrated clinical documentation solutions for the US healthcare industry. MedQuist’s operating income was $13.29m, compared to $8.12m for the comparable period in 2009.
China-based clinical-stage biotechnology company BoomRay Pharmaceuticals and Novartis Pharma have signed an exclusive worldwide licence deal for an undisclosed preclinical radioligand therapy (RLT) asset in a deal worth up to $900m.